JPH0325408B2 - - Google Patents
Info
- Publication number
- JPH0325408B2 JPH0325408B2 JP15641481A JP15641481A JPH0325408B2 JP H0325408 B2 JPH0325408 B2 JP H0325408B2 JP 15641481 A JP15641481 A JP 15641481A JP 15641481 A JP15641481 A JP 15641481A JP H0325408 B2 JPH0325408 B2 JP H0325408B2
- Authority
- JP
- Japan
- Prior art keywords
- lectin
- gra
- cancer cells
- cancer
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 29
- 108090001090 Lectins Proteins 0.000 claims description 20
- 102000004856 Lectins Human genes 0.000 claims description 20
- 239000002523 lectin Substances 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229930182830 galactose Natural products 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 210000000170 cell membrane Anatomy 0.000 claims description 5
- 108010046016 Peanut Agglutinin Proteins 0.000 claims description 3
- 108010039491 Ricin Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000000872 buffer Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000013504 Triton X-100 Substances 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 239000001110 calcium chloride Substances 0.000 description 6
- 229910001628 calcium chloride Inorganic materials 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 101000614017 Homo sapiens Lysine-specific demethylase 3A Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100040581 Lysine-specific demethylase 3A Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920001542 oligosaccharide Chemical group 0.000 description 1
- 150000002482 oligosaccharides Chemical group 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (34)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15641481A JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
| DK292182A DK292182A (da) | 1981-10-01 | 1982-06-29 | Fremgangsmaade til fremstilling af lymfocytter, der er cytotoksiske overfor cancerceller, samt glyco-associeret antigen til anvendelse derved |
| FI822325A FI77157C (fi) | 1981-10-01 | 1982-06-29 | Foerfarande foer framstaellning av glykobunden antigen och foerfarande foer framstaellning av foer kancerceller toxiska lymfocyter, som aer specifika mot denna antigen. |
| PT75148A PT75148B (en) | 1981-10-01 | 1982-06-29 | Production process of the lymphocytes fighting against cancero us cells and anti-cancer agents containing them |
| NZ201112A NZ201112A (en) | 1981-10-01 | 1982-06-29 | Preparation of a cancer-specific antigen and composition |
| HU210282A HU190803B (en) | 1981-10-01 | 1982-06-29 | Lymphocytes against carcinoma cells, process for producing them, and citostatic active agents containing the said lymphocytes |
| NO822215A NO161601C (no) | 1981-10-01 | 1982-06-29 | Fremgangsmaate for fremstilling av et glykorelatert antigen |
| AR289864A AR230731A1 (es) | 1981-10-01 | 1982-06-30 | Procedimiento para preparar un antigeno glicorrelacionado y un procedimiento para producir linfocitos citotoxicos para celulas cancerosas a partir de dicho antigeno glicorrelacionado |
| CA000406449A CA1201988A (en) | 1981-10-01 | 1982-06-30 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| BE0/208493A BE893704A (fr) | 1981-10-01 | 1982-06-30 | Lymphocytes luttant contre les cellules cancereuses, procede pour leur production et agents anticancereux contenant ces lymphocytes ou un antigene glyco-apparente |
| SE8204058A SE8204058L (sv) | 1981-10-01 | 1982-06-30 | Cancercellangripande lymfocyter, forfarande for framstellning derav och anticancermedel innehallande nemnda lymfocyter |
| MX8210163U MX7437E (es) | 1981-10-01 | 1982-06-30 | Procedimiento para producir un antigeno glico-relacionado |
| CH551284A CH655661B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-10-01 | 1982-06-30 | |
| PH27516A PH22474A (en) | 1981-10-01 | 1982-06-30 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| ES514450A ES8402615A1 (es) | 1981-10-01 | 1982-06-30 | Procedimiento para producir linfocitos citotoxicos de celulas de cancer utilizables en el tratamiento de este. |
| AU85458/82A AU554858B2 (en) | 1981-10-01 | 1982-06-30 | Glyco-related antigen from cancer cells |
| DD82261475A DD221917A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung von krebszellen-cytotoxischen lymphocyten |
| DD82241290A DD209577A5 (de) | 1981-10-01 | 1982-06-30 | Verfahren zur herstellung eines glykoverwandten antigens |
| IT48724/82A IT1189305B (it) | 1981-10-01 | 1982-06-30 | Linfociti che combattono cellule di cancro,procedimento per produrli ed agenti anticancerosi che li contengono |
| CH398882A CH655660B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1981-10-01 | 1982-06-30 | |
| NL8202638A NL8202638A (nl) | 1981-10-01 | 1982-06-30 | Kankercellenbestrijdende lymfocyten, werkwijze voor de produktie daarvan en antikankermiddelen, die deze lymfocyten bevatten. |
| FR8211489A FR2513882B1 (fr) | 1981-10-01 | 1982-06-30 | Lymphocytes luttant contre les cellules cancereuses, procede pour leur production et agents anticancereux contenant ces lymphocytes ou un antigene glyco-apparente |
| IL66270A IL66270A (en) | 1981-10-01 | 1982-07-08 | Cancer cell-derived glyco-related antigen,its production and anticancer agent containing it |
| DE19823249568 DE3249568A1 (de) | 1981-10-01 | 1982-09-30 | Glykoverwandtes antigen, verfahren zu dessen herstellung und dessen verwendung zur bekaempfung von krebs |
| DE19823236298 DE3236298A1 (de) | 1981-10-01 | 1982-09-30 | Krebszellen bekaempfende lymphocyten, verfahren zu deren herstellung und anti-krebsmittel, welche die lymphocyten enthalten |
| GB08228160A GB2106935B (en) | 1981-10-01 | 1982-10-01 | Cancer cell-combatting lymphocytes process for the production thereof and anticancer agents containing said lymphocytes |
| AT0363782A AT382080B (de) | 1981-10-01 | 1982-10-01 | Verfahren zur herstellung von glykoverwandtem antigen |
| CA000412670A CA1195269A (en) | 1981-10-01 | 1982-10-01 | Cancer cell-combatting lymphocytes, process for the production thereof and anticancer agents containing said lymphocytes |
| KR8204464A KR880001758B1 (ko) | 1981-10-01 | 1982-10-04 | 암세포에 대항하는 임파구의 제조방법 |
| ES523253A ES523253A0 (es) | 1981-10-01 | 1983-06-14 | "metodo de preparar antigenos glicorrelacionados". |
| IL75524A IL75524A0 (en) | 1981-10-01 | 1985-06-14 | Cancer cell-combating lymphocytes,their production and anticancer agents containing them |
| NO85853541A NO161128C (no) | 1981-10-01 | 1985-09-11 | Fremgangsmaate for fremstilling av kreftcelle-cytotokiske lymfocytter. |
| AT0354585A AT390002B (de) | 1981-10-01 | 1985-12-09 | Verfahren zur herstellung von krebszellen bekaempfenden lymphocyten |
| PH33696A PH23401A (en) | 1981-10-01 | 1986-04-23 | Cancer cell combatting lymphocytes,process for the production thereof and anti-cancer agents,containing said lymphocytes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15641481A JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5857321A JPS5857321A (ja) | 1983-04-05 |
| JPH0325408B2 true JPH0325408B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-04-05 |
Family
ID=15627222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15641481A Granted JPS5857321A (ja) | 1981-10-01 | 1981-10-01 | 抗癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5857321A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5967224A (ja) * | 1982-10-08 | 1984-04-16 | Nippon Koutai Kenkyusho:Kk | 糖鎖関連抗原およびその製造法ならびにこれを有効成分とする抗癌剤 |
| JPS62128903U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1986-02-08 | 1987-08-15 | ||
| JP2667765B2 (ja) * | 1991-08-09 | 1997-10-27 | 住友ゴム工業株式会社 | 空気入りタイヤ |
| US5660655A (en) * | 1991-08-09 | 1997-08-26 | Sumitomo Rubber Industries, Ltd. | Tire and rim combination with exhaust ribs in tire bead |
| CN114813264A (zh) * | 2020-01-19 | 2022-07-29 | 北京尧景基因技术有限公司 | 凝集素-磁性载体偶联复合物用于分离糖基化外泌体的应用 |
| CN114544290B (zh) * | 2020-01-19 | 2025-02-14 | 北京尧景基因技术有限公司 | 凝集素-大分子载体偶联复合物用于分离糖基化外泌体的应用 |
-
1981
- 1981-10-01 JP JP15641481A patent/JPS5857321A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5857321A (ja) | 1983-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0180564B1 (en) | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | |
| EP4442272A1 (en) | Vaccine adjuvant, and preparation method therefor and use thereof | |
| AU583402B2 (en) | Method for the production of a macromolecular carrier loaded with a biologically active substance | |
| CZ283037B6 (cs) | Látky polypeptidové povahy, způsob výroby a farmaceutické prostředky s jejich obsahem | |
| JPH0325408B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US5084441A (en) | Acetylated low density lipoproteins: a delivery system to phagocytic cells for stimulating immunologic response and host resistance | |
| US20170173115A1 (en) | Macrophage activating factor for pharmaceutical compositions | |
| JP2002519303A (ja) | 脂質動員性を有する糖タンパク質およびその治療的適用 | |
| JP5172864B2 (ja) | 抗腫瘍ワクチン、抗腫瘍ワクチンの調製方法及び抗腫瘍免疫療法の実行方法 | |
| Damadian | Ion exchange in Escherichia coli: potassium-binding proteins | |
| JPS60214737A (ja) | 糖鎖関連抗原の製造法 | |
| EP1419177A2 (en) | A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine | |
| AU2002321012A1 (en) | A purification process for large scale production of Gc-globulin, product obtained thereby and their use in medicine | |
| US4067964A (en) | Antihemophilic agent and process for its manufacture | |
| US7262167B2 (en) | Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites | |
| JPH0611705B2 (ja) | 血小板減少症治療剤 | |
| FI80711B (fi) | Foerfarande foer framstaellning av en terapeutiskt anvaendbar termiskt denaturerad, till en glykosidbindning ansluten antigen (gra), som haerroer sig fraon cancerceller. | |
| CN107753953A (zh) | 聚乙二醇化激肽原酶的制剂及其应用 | |
| JPS6338971B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP1085909B1 (en) | A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies | |
| FI77157C (fi) | Foerfarande foer framstaellning av glykobunden antigen och foerfarande foer framstaellning av foer kancerceller toxiska lymfocyter, som aer specifika mot denna antigen. | |
| JPS59225119A (ja) | 熱変性抗原の製造法 | |
| US8679780B2 (en) | Method of reducing immunological tolerance to malignancy | |
| JPS5857318A (ja) | 癌細胞障害性リンパ球の製造法 | |
| KR20020001817A (ko) | 병상맥관형성 질환의 예방 또는 감쇠 방법 |